Author: Ken Dropiewski

ZOLL Medical Receives FDA Clearance for TBI Dashboard on Its Propaq M Monitor and Propaq MD Monitor/Defibrillator

CHELMSFORD, Mass.–(BUSINESS WIRE)–ZOLL® Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, today announced that it has received FDA 510(k) clearance to release the TBI Dashboard™ feature on its Propaq® M monitor and Propaq MD monitor/defibrillator. TBI Dashboard provides clinical decision support for managing patients […]

BioVentrix Announces Raymond W. Cohen as Chairman of the Board and Newly Appointed Accredited Public Company Directors Rinda K. Sama and Andrew G. Hinson to Its Board of Directors

SAN RAMON, Calif.–(BUSINESS WIRE)–BioVentrix, Inc., a privately held medical device company focused on treating congestive heart failure via Transcatheter Ventricular Restoration (TCVR), today announced the appointment of Raymond W. Cohen as the Company’s chairman and named Rinda K. Sama and Andrew G. Hinson to its board of directors. Mr. Cohen […]

NIMIUM Therapeutics and Paraza Pharma form partnership to develop new medicines to treat cardiometabolic diseases (CMDs), obesity and type 2 diabetes

Innovative partnership focuses on early-stage development of activators for a glucose detoxification enzyme called glycerol-3-phosphate phosphatase (G3PP) MONTREAL, July 20, 2021 /PRNewswire/ — NIMIUM Therapeutics (www.nimium.ca), a Montreal-based biotech, has formed a partnership with Paraza Pharma (www.parazapharma.com) to develop a new treatment for cardiometabolic diseases (CMDs). The treatment aims to prevent and reverse the adverse […]

Pharmanovia expands strategic collaboration with M8 Pharmaceuticals in Latin America

MEXICO CITY, July 20, 2021 /PRNewswire/ — m8 Pharmaceuticals and Pharmanovia have signed an exclusive licensing agreement for a portfolio of several brands for Mexico & Brazil. This portfolio is comprised of well-known established brands for the treatment of cardiovascular, nervous system, and rheumatological illnesses. The main goal of the partnership is to continue to strengthen […]

Rivus Pharmaceuticals Launches with $35 Million Series A Financing to Develop Novel Treatments for Cardio-Metabolic Diseases

Advancing a pipeline of first-in-class Controlled Metabolic Accelerators (CMAs) to harness the body’s natural processes to improve cellular metabolism and treat the underlying causes of poor metabolic health and cardiovascular disease Initial programs to focus on type 2 diabetes, severe hypertriglyceridemia (SHTG), non-alcoholic steatohepatitis (NASH), heart failure with preserved ejection […]

Novocardia™ Announces Partnership with First Coast Heart & Vascular Cente

Alliance to Focus on Improving the Quality, Access, and Value of Cardiovascular Disease Care in Northeast Florida NEW YORK, July 20, 2021 /PRNewswire/ — Novocardia, a value-based cardiovascular disease care delivery platform, today announced a partnership with First Coast Heart & Vascular Center, P.C., the largest independent cardiovascular disease physician group in Northeast […]

CARMAT announces the first commercial implant of its Aeson® artificial heart

The implant, performed at the Azienda Ospedaliera dei Colli hospital in Naples, Italy, represents the first sale for CARMATand paves the way for the Company’s commercial development PARIS–(BUSINESS WIRE)–Regulatory News: CARMAT (Paris:ALCAR) (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to provide a […]

Anthos Therapeutics’ novel Factor XI inhibitor abelacimab significantly outperforms standard of care enoxaparin in prospective Phase 2 efficacy research published today in the New England Journal of Medicine

Abelacimab achieved a ~80% reduction in venous thromboembolism versus a standard of care comparator in gold standard proof-of-concept efficacy study, indicating its potential in a range of thromboembolic disorders CAMBRIDGE, Mass., July 19, 2021 /PRNewswire/ — Anthos Therapeutics, a clinical-stage biopharma company developing innovative therapies for cardiovascular and metabolic diseases, today announced final […]

Cytokinetics Announces Positive Topline Results of Redwood-HCM

Phase 2 Clinical Trial of CK-274 Demonstrated Consistent and Clinically Meaningful Reductions in Left Ventricular Outflow Tract Gradients Within Two Weeks in Patients with Obstructive Hypertrophic Cardiomyopathy No Treatment Interruptions or Discontinuations Due to Reduction in Left Ventricular Ejection Fraction Phase 3 Registrational Trial of CK-274 Expected to Start Before […]